Recurrent missense mutations in TMEM43 (ARVD5) due to founder effects cause arrhythmogenic cardiomyopathies in the UK and Canada
Annika Haywood(Memorial University of Newfoundland), Terry‐Lynn Young(Memorial University of Newfoundland), Perry Elliott(St Bartholomew's Hospital), William J. McKenna(British Heart Foundation), Petros Syrris(University College Hospital), Antonios Pantazis, Kathy Hodgkinson(St. Mary’s Hospital), Valerie Booth(Memorial University of Newfoundland), Giovanni Quarta(University College Hospital), Jim Houston(Memorial University of Newfoundland), Sean P. Connors, Nancy D. Merner(Montreal Neurological Institute and Hospital)
Cited by 57
Related Papers
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k
Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies
|Circulation|1996|3.5k
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2013|3.4k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k